Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 8/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3076619 | 0.79 | ALDH1A1 (0.48) | ABCB1HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL6745840 | 0.79 | MEN1 (0.48) | ABCB1KMT2AMEN1ATMPKM | |
| SCHEMBL17251631 | 0.78 | MEN1 (0.46) | ABCB1HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL17241772 | 0.78 | MEN1 (0.46) | ABCB1HTTL3MBTL1KMT2AMEN1 | |
| SCHEMBL5698940 | 0.77 | MEN1 (0.52) | ABCB1KMT2AMEN1ATMPKM | |
| SCHEMBL3065195 | 0.77 | ABCB1 (0.44) | ABCB1L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL16112113 | 0.77 | TDP1 (0.39) | HTTKMT2AMEN1CYP2D6CYP2C19 | |
| SCHEMBL7526130 | 0.77 | ABCB1 (0.49) | ABCB1KMT2AMEN1ATMPKM | |
| SCHEMBL7530991 | 0.75 | ABCB1 (0.48) | ABCB1KMT2AMEN1ATMPKM | |
| SCHEMBL7277526 | 0.73 | KMT2A (0.54) | HTTL3MBTL1KMT2AMEN1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0889042-B1 | RADICICOL DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053990-A1 | Radicicol derivatives | KYOWA HAKKO KOGYO CO., LTD (JP) | 2004-03-18 | — | — | US | disclosed |
| US-6635662-B2 | A 2-oxime derivative; antitumor and -carcinogenic agents; immunosuppressents; osteoporosis; enzyme inhibitors of tyrosine kinase activity | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-21 | — | — | US | disclosed |
| US-6316491-B1 | INHIBITORS OF TYROSINE KINASE USED AS ANTITUMOR OR IMMUNOSUPPRESSION AGENTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
| US-20010027208-A1 | Radicicol derivatives | INO YOJI (JP) | 2001-10-04 | — | — | US | disclosed |
| US-6239168-B1 | ANTITUMOR AGENTS, IMMUNOSUPPRESSANTS; TYROSINE KINASE INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-0889042-A1 | RADICICOL DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053990-A1 | Radicicol derivatives | ROS1, LYN, SRC | ABCB1 3873/4885HTT 4255/4885L3MBTL1 259/4885 |
| US-20010027208-A1 | Radicicol derivatives | ROS1, LYN, SRC | ABCB1 3853/4885HTT 4134/4885L3MBTL1 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.